CD19 CAR T-Cell Therapy Effective for Relapsed/Refractory DLBCL – Cancer Network
|
CD19 CAR T-Cell Therapy Effective for Relapsed/Refractory DLBCL
Cancer Network According to the study, only about half of patients with relapsed or refractory DLBCL are candidates for treatment with high-dose chemotherapy with autologous stem cell transplantation, and even among those treated with this approach, the 3-year event … |
